KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma.

Mitra MehradSomak RoyWilliam A LaFramboisePatti PetroskoCaitlyn MillerPimpin IncharoenSanja Dacic

Published in: Histopathology (2018)

Potentially targetable mutations can be identified in a subset of PSC, although most tumours harbour currently untargetable prognostically adverse TP53 and KRAS mutations.

Keyphrases

wild type
pulmonary hypertension
adverse drug